HAE
Haemonetics CorpPrice & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings per diluted share non-GAAP | $4.96 | Fiscal 2026 | — |
|
|
|||
| Adjusted gross margin non-GAAP | 59.7% | Q4 | — |
|
|
|||
| Adjusted operating margin non-GAAP | 24.4% | Q4 | — |
|
|
|||
| Free cash flow | $210M | Fiscal 2026 | — |
| Organic ex-CSL revenue increase non-GAAP | 7.5% | 3rd Quarter 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HAE
this stock
Haemonetics Corp
|
$3.35B | -7.9% | +12.0% | 36.0 | 6.6% |
|
ABT
Abbott Laboratories
|
$164.43B | -23.6% | +5.7% | 26.4 | 1.3% |
|
SYK
Stryker Corp
|
$125.30B | -6.8% | +11.2% | 37.8 | 1.6% |
|
MDT
Medtronic plc
|
$104.98B | -13.9% | +8.4% | 22.0 | 1.4% |
|
BSX
Boston Scientific Corp
|
$66.60B | -53.0% | +5.5% | 18.8 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HAE | -1.6% | -1.4% | -6.3% | -1.6% | -7.9% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -1.4% | -2.3% | -13.8% | -1.4% | -17.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.